[Placental transfer and pharmacokinetic parameters of flomoxef during the perinatal period].
Flomoxef (FMOX), a new oxacephem with low MIC values against not only Gram-negative bacilli (GNB) but also against Gram-positive cocci (GPC), was evaluated for its transfer into fetus, amniotic fluid, maternal milk, spinal fluid and urine during the perinatal period following a single intravenous drip infusion at a dose of 1 g for 30 minutes. The results obtained are summarized below. 1. High concentrations of FMOX were demonstrated in maternal serum, umbilical arterial serum and amniotic fluid with Cmax values of 48.0, 10.99 and 10.20 micrograms/ml, respectively. 2. Maternal urinary excretion rate was 65.4% in the first 6 hours after administration. 3. In contrast, maternal milk and spinal fluid levels were lower than 3 and 0.20 micrograms/ml, respectively. These results showed a good placental transfer of FMOX, which is very useful for various perinatal infections. No adverse effects were observed in mothers and neonates during the course of this study.
Makinoda
S
S
Department of Obstetrics and Gynecology, Hokkaido University School of Medicine.
Tsuruta
H
H
Iwaki
M
M
Negishi
H
H
Hanatani
K
K
Tanaka
T
T
Fujimoto
S
S
D000328:Adult; D000653:Amniotic Fluid / Q000378:metabolism; D002511:Cephalosporins / Q000008:administration & dosage / Q000493:pharmacokinetics*; D005260:Female; D005312:Fetal Blood / Q000378:metabolism; D006801:Humans; D007262:Infusions, Intravenous; D008431:Maternal-Fetal Exchange; D008895:Milk, Human / Q000378:metabolism; D008954:Models, Biological; D011247:Pregnancy
D002511:Cephalosporins; C045693:flomoxef